|
Jun 13
|
Novo Nordisk Is Europe’s Most Valuable Company—Again. Eli Lilly, Watch Out.
|
|
Jun 13
|
Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?
|
|
Jun 13
|
NVO Stock up on Plans to Advance Obesity Candidate Amycretin
|
|
Jun 13
|
Company News for Jun 13, 2025
|
|
Jun 13
|
Novo Nordisk ramps up obesity fight, advances amycretin to Phase III
|
|
Jun 13
|
Trending tickers: Boeing, Adobe, Exxon, Oracle and Novo Nordisk
|
|
Jun 13
|
Novo Nordisk regains crown as Europe's most valuable company
|
|
Jun 12
|
Why Novo Nordisk Stock Pumped Higher on Thursday
|
|
Jun 12
|
Why Novo Nordisk (NVO) Outpaced the Stock Market Today
|
|
Jun 12
|
Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year
|
|
Jun 12
|
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
|
|
Jun 12
|
Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs
|
|
Jun 12
|
4 Dividend Stocks to Double Up on Right Now
|
|
Jun 11
|
Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies
|
|
Jun 11
|
NVO Stock Gains After Parvus Asset Management Builds Stake
|
|
Jun 11
|
Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?
|
|
Jun 11
|
Eli Lilly telehealth partners continue to sell compounded GLP-1 weight-loss drugs despite agreement not to
|
|
Jun 11
|
Nvidia Teams With Novo Nordisk to Supercharge Early-Stage Drug R&D
|
|
Jun 11
|
Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple
|
|
Jun 11
|
The cheap fat jabs sending big pharma into a frenzy
|